NOBL vs XBI
ProShares S&P 500 Dividend Aristocrats ETF vs SPDR S&P Biotech ETF
- • NOBL pays a higher dividend yield (2.09%).
Side-by-side metrics
| Metric | NOBL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.09% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $11.30B | $8.30B |
YTD return | 4.12% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.71 | 1.09 |
P/E ratio | 22.66 | — |
Last price | $107.43 | $133.66 |
Inception | — | — |
Issuer | ProShares | State Street |
NOBL top holdings
| CAT | Caterpillar Inc | 2.02% |
| NUE | Nucor Corp | 1.83% |
| TGT | Target Corp | 1.79% |
| BEN | Franklin Resources Inc | 1.73% |
| NEE | NextEra Energy Inc | 1.71% |
| WST | West Pharmaceutical Services Inc | 1.71% |
| CVX | Chevron Corp | 1.70% |
| XOM | Exxon Mobil Corp | 1.69% |
| LIN | Linde PLC | 1.67% |
| APD | Air Products and Chemicals Inc | 1.67% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About NOBL
NOBL (ProShares S&P 500 Dividend Aristocrats ETF) is S&P 500 names with 25+ years of dividend growth. Managed by ProShares, the fund carries $11.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 2.09%. Its largest holding is Caterpillar Inc (CAT), which represents 2.0% of the portfolio. Real Estate is the fund's largest sector exposure at 4.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.